Antimicrobial Resistance Diagnostics Markets: Market Forecast, Competitive Landscape, Technology and Policy Outlook, 2027-2031

Antimicrobial resistance is rising faster than new antibiotics arrive, and diagnostics that find resistance quickly are moving to the centre of hospital care. This report estimates the global antimicrobial resistance diagnostics market at $3,460 million in 2026, growing 9.3% a year to $5,400 million in 2031 and adding $1,940 million of new annual spending. Culture and phenotypic susceptibility testing remain the base of the market but fall from 51.5% to 42.0% of it, while rapid phenotypic AST grows fastest, at 24.4% a year from $190.3 million to $567.0 million, followed by NGS and metagenomics at 23.7%. Carbapenem-resistant Enterobacterales (CRE) is the fastest-growing pathogen group, at 14.1% a year, and bloodstream infection and sepsis is the largest infection site, rising from $986.1 million to $1,674.0 million.

The past year reshaped the industry. Bruker bought the former Accelerate Diagnostics rapid-AST business, T2 Biosystems liquidated, OpGen left diagnostics as CapForce, and Waters took over BD's microbiology business, including Phoenix, BACTEC and Kiestra. The FDA cleared expanded rapid AST menus from Q-linea and bioMerieux and the first susceptibility tests for the new antibiotic gepotidacin, and the World Health Assembly adopted the Global Action Plan on AMR for 2026-2036. The report covers 23 chapters, 68 tables and 54 figures, with forecasts by pathogen, technology, infection site, purpose and product for 14 countries and regions, and profiles of 40 companies.

Get our research team working for you by ordering this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information.

Product Code: IDAMRDx 1126

List of Tables

List of Figures

1. Executive Summary

1.1 Situation Analysis
1.2 Market Snapshot
1.3 Key Findings
1.4 Investment & Strategic Thesis

2. Research Methodology & Scope

2.1 Scope & Market Definition
2.2 Value Basis
2.3 Market Segments
2.4 Geographic Coverage
2.5 Methodology
2.6 Sources
2.7 Author
2.8 Limitations

3. Introduction to Antimicrobial Resistance & AMR Diagnostics

3.1 What is Antimicrobial Resistance?
3.2 How Bacteria Resist Antibiotics
3.3 The Burden of AMR
3.4 Why Diagnostics Matter
3.5 From Culture to MALDI-TOF, PCR and Rapid AST
3.6 The Industry and Its Players

4. The Global Market for Antimicrobial Resistance Diagnostics

4.1 Global Market Overview by Country
4.2 Global Market by Pathogen - Overview
4.3 Global Market by Technology - Overview
4.4 Global Market by Infection Site - Overview
4.5 Global Market by Purpose - Overview
4.6 Global Market by Product - Overview

5. Phenotypic & Rapid Antimicrobial Susceptibility Testing

5.1 The Workhorse of the Market
5.2 Automated AST: Installed Base and Leaders
5.3 Breakpoints and the Update Problem
5.4 Rapid Phenotypic AST Technologies and Companies
5.5 The Positive Blood Culture Workflow
5.6 Time-to-Result Economics

6. Molecular Resistance Testing: PCR, Syndromic Panels & NGS

6.1 Resistance Genes versus Phenotype
6.2 PCR Tests for Resistant Organisms
6.3 Syndromic Panels with Resistance Markers
6.4 NGS and Metagenomics
6.5 The Genotype-Phenotype Gap
6.6 Casualties and Consolidation

7. Priority Pathogens: Clinical Need & Testing by Pathogen

7.1 MRSA
7.2 VRE
7.3 CRE
7.4 ESBL
7.5 Drug-Resistant Gonorrhoea
7.6 C. difficile
7.7 Drug-Resistant S. pneumoniae
7.8 Enteric and Other Pathogens
7.9 Pathogen Segments Compared

8. Sepsis, Bloodstream Infection & Antimicrobial Stewardship

8.1 Sepsis Burden and the Cost of Delay
8.2 From Blood Culture to Identification and AST
8.3 Host-Response Tests as Context
8.4 Antimicrobial Stewardship Programmes and Requirements
8.5 Evidence on Outcomes and Cost
8.6 Market Implications

9. Infection Control, Screening & One Health Surveillance

9.1 Active Surveillance Screening for Resistant Organisms
9.2 Outbreak Response and Hospital Typing
9.3 National and International Surveillance Systems
9.4 The Global Action Plan on AMR 2026-2036
9.5 One Health: Animal, Food and Environmental Surveillance
9.6 Market Dynamics

10. Regulation, Reimbursement & AMR Policy

10.1 United States: FDA Pathways
10.2 Breakpoints: CLSI, EUCAST and the FDA
10.3 Europe, China and Other Regulators
10.4 Reimbursement
10.5 Antibiotic Pull Incentives
10.6 Push Funding and Global Initiatives
10.7 Outlook

11. China, India & Emerging-Market AMR Diagnostics

11.1 The Burden of Resistance
11.2 China
11.3 India
11.4 Africa and the Fleming Fund
11.5 Latin America, the Middle East and Other Markets
11.6 Pricing and Market Access
11.7 Outlook

12. Recent Developments

12.1 Importance and Use of This Section
12.2 Bruker Acquires AST Revolution, the Former Accelerate Diagnostics Rapid AST Business
12.3 T2 Biosystems Announces It Will Wind Down and Liquidate
12.4 World Health Assembly Adopts the Updated Global Action Plan on AMR 2026-2036
12.5 FDA Clears Q-linea's Expanded ASTar Gram-Negative Blood Culture Menu
12.6 GO-Dx Diagnostics Access Compact Launched at the One Health Summit in Lyon
12.7 Pattern Bioscience Passes 1,000 Samples in US Trial of Its Pneumonia ID/AST Panel
12.8 CARB-X 2026 Funding Round Includes Diagnostics for Neonatal Sepsis
12.9 Bruker Presents Its Rapid AST Workflow and Expanded MALDI Biotyper Claims at ASM Microbe 2026
12.10 First Susceptibility Tests Cleared for GSK's Gepotidacin
12.11 OpGen Renames Itself CapForce and Leaves Diagnostics

13. Operations, Laboratory Workflow & Supply Chain

13.1 The Microbiology Workflow
13.2 Laboratory Automation
13.3 Staffing Shortages
13.4 Reagents, Consumables and the Supply Chain
13.5 Data, LIS Connectivity and Surveillance Reporting
13.6 Artificial Intelligence in Microbiology
13.7 Operational Outlook

14. Competitive Landscape

14.1 Market Structure
14.2 Leaders by Technology
14.3 Emerging and China-Originated Players
14.4 Outlook

15. SWOT, Porter's Five Forces & Investment Risk Analysis

15.1 SWOT Analysis
15.2 Porter's Five Forces
15.3 Investment Risk Analysis

16. Strategic Recommendations

16.1 Guidance for Executives, Marketing, Sales and Business Development
16.2 Guidance for Management Consultants and Investment Advisors

17. Market Forecast by Pathogen, 2026-2031

17.1 MRSA
17.2 VRE
17.3 CRE
17.4 ESBL
17.5 DR Gonorrhea
17.6 C. difficile
17.7 DR S. pneumoniae
17.8 Enteric & Other

18. Market Forecast by Technology, 2026-2031

18.1 Culture & Phenotypic AST
18.2 Rapid Phenotypic AST
18.3 Immunoassay & LFA
18.4 PCR
18.5 Syndromic Panels
18.6 NGS & Metagenomics
18.7 Mass Spectrometry

19. Market Forecast by Infection Site, 2026-2031

19.1 Bloodstream & Sepsis
19.2 Respiratory
19.3 Urinary Tract
19.4 Gastrointestinal
19.5 Sexually Transmitted
19.6 Skin, Wound & Other

20. Market Forecast by Purpose, 2026-2031

20.1 Diagnosis & Therapy
20.2 Screening & Infection Control
20.3 Surveillance & Public Health

21. Market Forecast by Product, 2026-2031

21.1 Reagents & Consumables
21.2 Instruments
21.3 Software & Services

22. Company Profiles

22.1 Abbott Laboratories
22.2 Affinity Biosensors (LifeScale)
22.3 Alifax
22.4 Beckman Coulter (Danaher)
22.5 Biocartis
22.6 bioMerieux
22.7 Bio-Rad Laboratories
22.8 Bruker
22.9 Cepheid (Danaher)
22.10 Copan Diagnostics
22.11 DiaSorin (Luminex)
22.12 Eurofins Scientific
22.13 Genetic Signatures
22.14 Gradientech
22.15 Hardy Diagnostics
22.16 Hologic
22.17 Illumina
22.18 Inflammatix
22.19 Karius
22.20 Liofilchem
22.21 Lumos Diagnostics
22.22 MilliporeSigma (Merck KGaA)
22.23 Mindray
22.24 Momentum Bioscience
22.25 Oxford Nanopore Technologies
22.26 Pattern Bioscience
22.27 Qiagen
22.28 Q-linea
22.29 QuidelOrtho
22.30 Resistell
22.31 Revvity
22.32 Roche Diagnostics
22.33 Scope Fluidics
22.34 Seegene
22.35 Selux Diagnostics
22.36 Siemens Healthineers
22.37 Sysmex
22.38 Thermo Fisher Scientific
22.39 Visby Medical
22.40 Waters Corporation (formerly BD Diagnostic Solutions)

23. Appendix

23.1 Abbreviations
23.2 Developments Archive
23.3 Report Limitations Restated

Product Code: IDAMRDx 1126

List of Tables

Table 1 Key Market Indicators (constant 2026 US$)
Table 2 Leading AMR Diagnostic Products, October 2026
Table 3 Main Mechanisms of Antibacterial Resistance
Table 4 WHO Bacterial Priority Pathogens List 2024 and Report Segments
Table 5 Milestones in AMR Diagnostics
Table 6 Global Market by Country
Table 7 Global Market by Pathogen
Table 8 Global Market by Technology
Table 9 Global Market by Infection Site
Table 10 Global Market by Purpose
Table 11 Global Market by Product
Table 12 Phenotypic AST Segments, 2026 and 2031
Table 13 Main Phenotypic AST Platforms and Methods
Table 14 Selected Rapid Phenotypic AST Systems
Table 15 Positive Blood Culture: Conventional versus Rapid Workflow
Table 16 Molecular Resistance Testing Segments, 2026 and 2031
Table 17 Selected PCR Tests for Resistant Organisms
Table 18 Selected Syndromic Panels with Resistance Markers
Table 19 AMR Diagnostics by Pathogen Group, 2026 and 2031 (US$ Millions)
Table 20 Positive Blood Culture Workflow: Conventional and Rapid
Table 21 Stewardship and Sepsis Requirements Affecting AMR Diagnostics
Table 22 Main Screening Programmes for Resistant Organisms
Table 23 Major AMR Surveillance Systems
Table 24 Regulatory Routes for AMR Diagnostics
Table 25 Main Push Funding Sources and Initiatives for AMR Diagnostics
Table 26 AMR Diagnostics Market in China and Emerging Markets, 2026 and 2031
Table 27 Emerging-Market AMR Testing by Tier
Table 28 Recent Developments Covered in This Section
Table 29 Typical Steps and Timings in Bacterial Resistance Testing
Table 30 Competitive Structure by Technology
Table 31 Leading Suppliers in Culture and Phenotypic AST
Table 32 Leading Suppliers in Rapid Phenotypic AST
Table 33 Leading Suppliers in PCR and Syndromic Panels
Table 34 Leading Suppliers in NGS and Mass Spectrometry
Table 35 Selected Emerging AMR Diagnostics Companies
Table 36 SWOT Analysis - Strengths and Weaknesses
Table 37 SWOT Analysis - Opportunities and Threats
Table 38 Porter's Five Forces Ratings
Table 39 Investment Risk Matrix
Table 40 Selected Growth Opportunities
Table 41 MRSA by Country
Table 42 VRE by Country
Table 43 CRE by Country
Table 44 ESBL by Country
Table 45 DR Gonorrhea by Country
Table 46 C. difficile by Country
Table 47 DR S. pneumoniae by Country
Table 48 Enteric & Other by Country
Table 49 Culture & Phenotypic AST by Country
Table 50 Rapid Phenotypic AST by Country
Table 51 Immunoassay & LFA by Country
Table 52 PCR by Country
Table 53 Syndromic Panels by Country
Table 54 NGS & Metagenomics by Country
Table 55 Mass Spectrometry by Country
Table 56 Bloodstream & Sepsis by Country
Table 57 Respiratory by Country
Table 58 Urinary Tract by Country
Table 59 Gastrointestinal by Country
Table 60 Sexually Transmitted by Country
Table 61 Skin, Wound & Other by Country
Table 62 Diagnosis & Therapy by Country
Table 63 Screening & Infection Control by Country
Table 64 Surveillance & Public Health by Country
Table 65 Reagents & Consumables by Country
Table 66 Instruments by Country
Table 67 Software & Services by Country
Table 68 Abbreviations Used in This Report

List of Figures

Figure 1 Key Graphic - Faster Answers Win: AMR Diagnostics Market by Technology, 2026 vs 2031
Figure 2 Global Market Pareto Chart
Figure 3 Global Market by Pathogen - Base vs. Final
Figure 4 Global Market by Pathogen Base Year
Figure 5 Global Market by Pathogen End Year
Figure 6 Pathogen Share by Year
Figure 7 Pathogen Segments Growth
Figure 8 Global Market by Technology - Base vs. Final
Figure 9 Global Market by Technology Base Year
Figure 10 Global Market by Technology End Year
Figure 11 Technology Share by Year
Figure 12 Technology Segments Growth
Figure 13 Global Market by Infection Site - Base vs. Final
Figure 14 Global Market by Infection Site Base Year
Figure 15 Global Market by Infection Site End Year
Figure 16 Infection Site Share by Year
Figure 17 Infection Site Segments Growth
Figure 18 Global Market by Purpose - Base vs. Final
Figure 19 Global Market by Purpose Base Year
Figure 20 Global Market by Purpose End Year
Figure 21 Purpose Share by Year
Figure 22 Purpose Segments Growth
Figure 23 Global Market by Product - Base vs. Final
Figure 24 Global Market by Product Base Year
Figure 25 Global Market by Product End Year
Figure 26 Product Share by Year
Figure 27 Product Segments Growth
Figure 28 MRSA Growth
Figure 29 VRE Growth
Figure 30 CRE Growth
Figure 31 ESBL Growth
Figure 32 DR Gonorrhea Growth
Figure 33 C. difficile Growth
Figure 34 DR S. pneumoniae Growth
Figure 35 Enteric & Other Growth
Figure 36 Culture & Phenotypic AST Growth
Figure 37 Rapid Phenotypic AST Growth
Figure 38 Immunoassay & LFA Growth
Figure 39 PCR Growth
Figure 40 Syndromic Panels Growth
Figure 41 NGS & Metagenomics Growth
Figure 42 Mass Spectrometry Growth
Figure 43 Bloodstream & Sepsis Growth
Figure 44 Respiratory Growth
Figure 45 Urinary Tract Growth
Figure 46 Gastrointestinal Growth
Figure 47 Sexually Transmitted Growth
Figure 48 Skin, Wound & Other Growth
Figure 49 Diagnosis & Therapy Growth
Figure 50 Screening & Infection Control Growth
Figure 51 Surveillance & Public Health Growth
Figure 52 Reagents & Consumables Growth
Figure 53 Instruments Growth
Figure 54 Software & Services Growth

Antimicrobial Resistance Diagnostics Markets: Market Forecast, Competitive Landscape, Technology and Policy Outlook, 2027-2031

Description

Table of Contents

List of Tables

Report Overview:

Table of Contents

List of Tables

List of Figures

1. Executive Summary

2. Research Methodology & Scope

3. Introduction to Antimicrobial Resistance & AMR Diagnostics

4. The Global Market for Antimicrobial Resistance Diagnostics

5. Phenotypic & Rapid Antimicrobial Susceptibility Testing

6. Molecular Resistance Testing: PCR, Syndromic Panels & NGS

7. Priority Pathogens: Clinical Need & Testing by Pathogen

8. Sepsis, Bloodstream Infection & Antimicrobial Stewardship

9. Infection Control, Screening & One Health Surveillance

10. Regulation, Reimbursement & AMR Policy

11. China, India & Emerging-Market AMR Diagnostics

12. Recent Developments

13. Operations, Laboratory Workflow & Supply Chain

14. Competitive Landscape

15. SWOT, Porter's Five Forces & Investment Risk Analysis

16. Strategic Recommendations

17. Market Forecast by Pathogen, 2026-2031

18. Market Forecast by Technology, 2026-2031

19. Market Forecast by Infection Site, 2026-2031

20. Market Forecast by Purpose, 2026-2031

21. Market Forecast by Product, 2026-2031

22. Company Profiles

23. Appendix

List of Tables

List of Figures